Next-Generation Breast Cancer Diagnostic and Screening Global Market to 2032: Growing Scope for Molecular Breast Cancer Diagnosis Techniques in Emerging Countries Presents Opportunities - ResearchAndMarkets.com

The "Next-Generation Breast Cancer Diagnostic and Screening Market - A Global Market and Regional Analysis: Focus on Technology, Cancer Sub-Type, Biomarker, Offering, End User, and Country Analysis - Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.

The global next-generation breast cancer diagnostic and screening market was valued at $3,137.4 million in 2022 and is anticipated to reach $9,880.1 million by 2032, witnessing a CAGR of 12.57% during the forecast period 2023-2032.

The growth in the global next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases globally, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.

Market Lifecycle Stage

The next-generation breast cancer diagnostic and screening market is in the developing phase. Technological advancements in the development of next-generation breast cancer diagnostics and the growing scope for molecular breast cancer diagnosis techniques in emerging countries can be some of the major opportunities in the global next-generation breast cancer diagnostic and screening market.

Furthermore, some of the key trends going on in the market are the implementation of liquid biopsy for breast cancer diagnosis and the complete automation of next-generation techniques.

Recent Developments in the Global Next-Generation Breast Cancer Diagnostic and Screening Market

• In April 2023, Syantra Inc., a Canada-based company, received CE mark approval for its Syantra DX breast cancer test.
• In March 2023, NeoGenomics, Inc. launched its RaDaR assay, which is a liquid biopsy test for minimal residual disease (MRD).
• In February 2023, HALO Diagnostics launched its new HALO pathway for early breast cancer detection.
• In January 2023, Agilent Technologies, Inc. acquired Avida Biomed, a company that develops high-performance NGS target enrichment workflows for cancer research.
• In October 2022, Lucence Diagnostics Pte Ltd entered into a distribution partnership with Omnigen, under which Omnigen would distribute Lucence Diagnostics Pte Ltd's LiquidHALLMARK assay in Turkey.
• In March 2022, Myriad Genetics, Inc. received the U.S. FDA approval for its BRACanalysis CDx for being used as a companion diagnostic test and for the identification of breast cancer patients who may benefit from Lynparza in early breast cancer stages.
• In February 2022, Laboratory Corporation of America Holdings acquired Personal Genome Diagnostics Inc., a company that deals in cancer genomics and provides an assortment of comprehensive liquid biopsy and tissue-based products.
• In January 2022, Agendia Inc. entered into a partnership with Illumina Inc. to expand genomic testing for breast cancer care.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, and market penetration.

Key Companies Profiled

• Abbott Laboratories
• Agendia Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• BGI Genomics Co., Ltd.
• CENTOGENE N.V.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Lucence Diagnostics Pte Ltd
• Myriad Genetics, Inc.
• Natera, Inc.

Market Dynamics

Drivers

• Increasing Prevalence of Breast Cancer Globally
• Increased Awareness Regarding Early Diagnosis of Breast Cancer
• Growing Focus on Breast Cancer Biomarkers for Effective Screening, Prognosis, and Personalized Treatment
• Increasing Partnerships and Collaborations amongst Market Players

Restraints

• High Cost of Tests and Requirement of High Capital Investment for Testing Set-Up
• Occurrence of False Positive and False Negative Results

Opportunities

• Technological Advancements in the Development of Next-Generation Breast Cancer Diagnostics
• Growing Scope for Molecular Breast Cancer Diagnosis Techniques in Emerging Countries

Market Segmentation

Segmentation 1: by Technology

• Real-Time PCR
• Immunohistochemistry (IHC)
• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Others

Based on technology, the global next-generation breast cancer diagnostic and screening market is expected to be dominated by the immunohistochemistry (IHC) segment.

Segmentation 2: by Biomarker

• BRCA1/2
• ER/PR Receptors
• HER-2
• Others

Based on biomarker, the global next-generation breast cancer diagnostic and screening market is dominated by the BRCA1/2 segment.

Segmentation 3: by Cancer Sub-Type

• Luminal A
• Luminal B
• Triple Negative/Basal Like
• Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

Based on cancer sub-type, the global next-generation breast cancer diagnostic and screening market is dominated by the luminal A segment.

Segmentation 4: by Offering

• Products
• Services

Based on offering, the global next-generation breast cancer diagnostic and screening market is dominated by the services segment.

Segmentation 5: by End User

• Hospitals and Clinics
• Diagnostic Centers and Reference Labs
• Academic and Research Institutes

Based on end user, the global next-generation breast cancer diagnostic and screening market is dominated by the hospitals and clinics segment.

Segmentation 6: by Region

• North America - U.S., Canada
• Europe - Germany, France, U.K., Italy, Spain, and Rest-of-Europe
• Asia-Pacific - Japan, China, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
• Latin America - Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World

Based on region, the global next-generation breast cancer diagnostic and screening market is dominated by North America.

For more information about this report visit https://www.researchandmarkets.com/r/nxwdm6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230526005213/en/